Taken together, TLR ligand induced IL-6 counter-regulates effector T cell responses in vivo and thus a combination therapy of TLR stimulation and IL-6 blockade may be an effective new approach for the therapy of infectious diseases. This evidence concerns the gene IL6 and infectious disease.